Skip to Main Content
Welcome to the Scientist.com Marketplace

Go to Main Navigation

B0084-474893

Nintedanib Impurity 6 (Intedanib Impurity 6)

BOC Sciences

Thumbnail image

DETAILS

  • Iupac: 2-hydroxy-3-[N-[4-[methyl-[2-(4-methylpiperazin-1-yl)acetyl]amino]phenyl]-C-phenylcarbonimidoyl]-1H-indole-6-carboxylic acid
  • Smiles: O=C(C1=CC(NC/2=O)=C(C=C1)C2=C(NC3=CC=C(N(C)C(CN4CCN(C)CC4)=O)C=C3)/C5=CC=CC=C5)O
  • Aliases: BIBF-1202; BIBF 1202; BIBF1202. (3Z)-2,3-Dihydro-3-[[[4-[methyl[(4-methyl-1-piperazinyl)acetyl]amino]phenyl]amino]phenylmethylene]-2-oxo-1H-indole-6-carboxylic acid;(Z)-3-(((4-(N-methyl-2-(4-methylpiperazin-1 -yl)acetamido)phenyl)amino)(phenyl)methylene)-2-oxoindoline-6-carboxylic acid;Nintedanib Impurity 5
  • Cas Number: 894783-71-2
  • Molecular Weight: 525.60
  • Molecular Formula: C30H31N5O4

DESCRIPTION

BIBF 1202 is the major in-vivo metabolite of BIBF 1120, which is an oral triple angiokinase inhibitor targeting VEGFR, PDGFR, FGFR. It is a related compound of Intedanib, which is an indolinone derivative that inhibits angiokinase and an antitumor agent. It is a novel treatment modality in oncology through blockade of the vascular endothelial growth factor (VEGF) signaling pathway thus inhibition of tumor angiogenesis.